Expert Opinion on Emerging Drugs

HIV entry and fusion inhibitors
pp. 1-7(7)
Author: Chantry D.

Potential therapeutic targets for neurokinin-1 receptor antagonists
pp. 9-21(13)
Author: Duffy R.A.

The clinical application of monoclonal antibody therapies in renal transplantation
pp. 23-37(15)
Authors: Dhanireddy K.K.; Xu H.; Mannon R.B.; Hale D.A.; Kirk A.D.

Advances in pharmacotherapy for tobacco dependence
pp. 39-53(15)
Authors: Foulds J.; Burke M.; Steinberg M.; Williams J.M.; Ziedonis D.M.

Emerging treatments in acute myeloid leukaemia
pp. 55-71(17)
Author: Kell J.

Emerging drugs in pancreatic cancer
pp. 73-89(17)
Authors: Ducreux M.; Boige V.; Malka D.

Emerging drugs for head and neck cancer
pp. 91-104(14)
Authors: Rhee J.C.; Khuri F.R.; Shin D.M.

Emerging DNA topoisomerase inhibitors as anticancer drugs
pp. 105-133(29)
Author: Denny W.A.

Histone modification enzymes: novel targets for cancer drugs
pp. 135-154(20)
Authors: Kristeleit R.; Stimson L.; Workman P.; Aherne W.

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
pp. 155-166(12)
Author: Holst J.J.

Emerging drugs for endometriosis
pp. 167-177(11)
Authors: Fedele L.; Berlanda N.

Emerging oral drugs for erectile dysfunction
pp. 179-189(11)
Authors: Briganti A.; Salonia A.; Gallina A.; Suardi N.; Rigatti P.; Montorsi F.

Superbugs & Superdrugs: A Focus on Antibacterials – 6th Annual SMi Conference
pp. 191-195(5)
Author: Georgopapadakou N.